IBBL (Integrated Biobank of Luxembourg) is pleased to be welcoming a delegation of Chinese healthcare professionals today for a visit of its state-of-the-art facilities in Dudelange. The visit will be an opportunity to exchange knowledge and best practices.
The visit to IBBL is part of the Chinese delegation’s broader tour of European facilities, which will allow the delegates to discover different biobanking operation models and compare them with the Chinese situation. The delegation includes the CEO and CTO of Genepoint – a Chinese manufacturer or cryogenic equipment for biobanks – as well biobankers from the Shanghai area the CEO and core board members of Health-100 – China’s largest medical examination organisation assisting over 30 million people through its 400 medical inspection centres. The delegation is accompanied by Dr. Zisis Kozlakidis, current Head of the Laboratory Services and Biobank Group at the International Agency for Research on Cancer (IARC) in Lyon, France, and Past President of the International Society for Biological and Environmental Repositories (ISBER).
The visit will specifically focus on the aspects pertaining to the set-up of biobanks and how automated/semi-automated systems can be integrated. Moreover, discussions will also cover IBBL’s Proficiency Testing (PT) scheme, which is of particular interest to the delegation given the recent launch of the programme in China in July 2018. The programme offers Chinese biobanks and laboratories an external quality assessment tool to verify the precision and accuracy of their biospecimen testing methods.
“The visit will be an interesting opportunity to exchange on biobanking best practices with our Chinese colleagues and further strengthen our collaboration. Indeed, we continuously seek occasions for knowledge transfer, in line with our efforts to promote the standardisation of biobanking operations globally”, says Dr. Fay Betsou, Chief Scientific Officer at IBBL.